|
| Wednesday, August 20, 2025 |
|
|
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle |
| In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. more info >> |
|
| Friday, June 20, 2025 |
|
|
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health |
| Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide. more info >> |
|
| Tuesday, March 25, 2025 |
|
|
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong |
| CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, 'CanSinoBIO' or the 'Company'), a leading player in China's vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&D innovation and strong commercial capabilities. more info >> |
|
| Wednesday, October 9, 2024 |
|
|
CanSino Receives Another Strong Boost |
| CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio. more info >> |
|
| Thursday, August 29, 2024 |
|
|
CanSinoBIO Reports Outstanding H1 2024 Performance |
| CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. more info >> |
|
| Friday, April 26, 2024 |
|
|
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine |
| On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong'an New Area of Hebei Province. more info >> |
|
| Wednesday, March 27, 2024 |
|
|
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough |
| In 2023, CanSinoBIO's meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident. more info >> |
|
|
|
